Patient P-03031

Synthetic patientONX-7 · Day 138 · 55–64 · M · baseline S16Open companion preview

Therapy response

Declining

Tolerance

Deteriorating

GI state

Stable

Inflammatory state

Stable

Nutritional resilience

Declining

Discontinuation risk

47%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S16
Day 102 CR-01 recommended — Clinician Review CR-01
Day 103 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 103 Patient accepted — Started CR-01 in the companion
Day 108 Deterioration detected before clinical escalation — Clinician Review CR-01

What changed?

Trajectory began diverging from predicted response on Day 103.

Primary contributors, last 14 days

Toxicity+9
Treatment adherence-8
Nutritional resilience-4
Inflammatory activity+3
GI instability+2

What helped?

Clinician Review CR-01Day 102
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

52%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 50
- WearableHRV 22 ms, trending down
Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 48 and rising
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Drug metabolism and exposure ↑20
- BloodToxicity index 44
Autonomic recovery ↓20
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 2.6 · butyrate capacity 46/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 21 ms
Sleep: 6.4 h
Steps: 4,955
Resting HR: 67 bpm

Daily log: GI score 48, nutritional resilience 45, adherence 74.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03463	48%	S11	GI-04	no change	55
P-03225	44%	S19	GI-04	improved	50
P-03382	44%	S01	GI-04	improved	56
P-03021	41%	S15	—	—	57
P-03218	41%	S20	—	—	56
P-03379	41%	S12	GI-04	improved	51
P-03280	40%	S13	—	—	57
P-03292	39%	S14	—	—	62
P-03120	37%	S14	—	—	61
P-03166	37%	S20	CR-01	improved	62
P-03191	37%	S19	GI-04	improved	51
P-03200	37%	S16	—	—	59